A new class of therapy, synthetic peptide immunoregulatory epitopes (SPIREs), is being researched by Adiga Life Sciences for grass and dust mite allergies. Patients who received the investigational treatment in a Phase II clinical trial had improved symptoms compared to those on placebo. With positive results shown with both dust mite and grass allergies, this type of treatment could possibly provide relief for many other types of allergies.
RNA interference (RNAi) is a potential new treatment for high cholesterol. In a Phase I clinical trial, Alnylam Pharmaceuticals found that a single dose of small interfering ribonucleic acid (siRNA) decreased levels of LDL (or “bad”) cholesterol by up to 57 percent. This class of drugs could become an option for the 1 in 5 people who are resistant to statins.
Researchers from Cardiff University’s School of Medicine and Peking University are working together to study the potential benefits of combining traditional Chinese medicine with traditional cancer treatments, such as chemotherapy. They also hope that new cancer treatments and therapies may be discovered through the union of these East and West medicines.
Read more about all of these studies here
